Kymera Therapeutics, Inc. - Common Stock (KYMR)

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Kymera's lead pipeline candidate received some good news.

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.

KYMR stock results show that Kymera Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Shares soared and then tumbled Friday after the company offered $275 million in public shares.

Although U.S. stocks closed slightly higher on Monday, there were a few notable insider trades.

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.